Literature DB >> 28664355

Using Multiple Pharmacovigilance Models Improves the Timeliness of Signal Detection in Simulated Prospective Surveillance.

Rolina D van Gaalen1, Michal Abrahamowicz2,3, David L Buckeridge2.   

Abstract

INTRODUCTION: Prospective pharmacovigilance aims to rapidly detect safety concerns related to medical products. The exposure model selected for pharmacovigilance impacts the timeliness of signal detection. However, in most real-life pharmacovigilance studies, little is known about which model correctly represents the association and there is no evidence to guide the selection of an exposure model. Different exposure models reflect different aspects of exposure history, and their relevance varies across studies. Therefore, one potential solution is to apply several alternative exposure models simultaneously, with each model assuming a different exposure-risk association, and then combine the model results.
METHODS: We simulated alternative clinically plausible associations between time-varying drug exposure and the hazard of an adverse event. Prospective surveillance was conducted on the simulated data by estimating parametric and semi-parametric exposure-risk models at multiple times during follow-up. For each model separately, and using combined evidence from different subsets of models, we compared the time to signal detection.
RESULTS: Timely detection across the simulated associations was obtained by fitting a set of pharmacovigilance models. This set included alternative parametric models that assumed different exposure-risk associations and flexible models that made no assumptions regarding the form/shape of the association. Times to detection generated using a simple combination of evidence from multiple models were comparable to those observed under the ideal, but unrealistic, scenario where pharmacovigilance relied on the single 'true' model used for data generation.
CONCLUSIONS: Simulation results indicate that, if the true model is not known, an association can be detected in a more timely manner by first fitting a carefully selected set of exposure-risk models and then generating a signal as soon as any of the models considered yields a test statistic value below a predetermined testing threshold.

Mesh:

Year:  2017        PMID: 28664355     DOI: 10.1007/s40264-017-0555-9

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  49 in total

1.  Comparison of alternative models for linking drug exposure with adverse effects.

Authors:  Michal Abrahamowicz; Marie-Eve Beauchamp; Marie-Pierre Sylvestre
Journal:  Stat Med       Date:  2011-11-17       Impact factor: 2.373

2.  Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood-stabilizers.

Authors:  Marie Tournier; Bernard Bégaud; Audrey Cougnard; Guy-Robert Auleley; Jean Deligne; Claudine Blum-Boisgard; Anne C M Thiébaut; Hélène Verdoux
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

3.  Comparison of algorithms to generate event times conditional on time-dependent covariates.

Authors:  Marie-Pierre Sylvestre; Michal Abrahamowicz
Journal:  Stat Med       Date:  2008-06-30       Impact factor: 2.373

4.  So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests.

Authors:  Karen N Conneely; Michael Boehnke
Journal:  Am J Hum Genet       Date:  2007-12       Impact factor: 11.025

5.  Is the weighted z-test the best method for combining probabilities from independent tests?

Authors:  Z Chen
Journal:  J Evol Biol       Date:  2011-01-24       Impact factor: 2.411

6.  Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules.

Authors:  Joshua J Gagne; Jeremy A Rassen; Alexander M Walker; Robert J Glynn; Sebastian Schneeweiss
Journal:  Epidemiology       Date:  2012-03       Impact factor: 4.822

7.  Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.

Authors:  Stephen P Motsko; Karen L Rascati; Anthony J Busti; James P Wilson; Jamie C Barner; Kenneth A Lawson; Jason Worchel
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

8.  Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events.

Authors:  K G Saag; R Koehnke; J R Caldwell; R Brasington; L F Burmeister; B Zimmerman; J A Kohler; D E Furst
Journal:  Am J Med       Date:  1994-02       Impact factor: 4.965

9.  Association between risk factors for injurious falls and new benzodiazepine prescribing in elderly persons.

Authors:  Gillian Bartlett; Michal Abrahamowicz; Roland Grad; Marie-Pierre Sylvestre; Robyn Tamblyn
Journal:  BMC Fam Pract       Date:  2009-01-06       Impact factor: 2.497

10.  Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis.

Authors:  Mohammad Movahedi; Marie-Eve Beauchamp; Michal Abrahamowicz; David W Ray; Kaleb Michaud; Sofia Pedro; William G Dixon
Journal:  Arthritis Rheumatol       Date:  2016-05       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.